{"id":126599,"date":"2021-08-22T04:23:44","date_gmt":"2021-08-22T11:23:44","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/08\/aaron-schacht-evp-innovation-regulatory-bd-elanco-well-being-of-animals-people-and-planet"},"modified":"2021-08-22T04:23:44","modified_gmt":"2021-08-22T11:23:44","slug":"aaron-schacht-evp-innovation-regulatory-bd-elanco-well-being-of-animals-people-and-planet","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/08\/aaron-schacht-evp-innovation-regulatory-bd-elanco-well-being-of-animals-people-and-planet","title":{"rendered":"Aaron Schacht \u2014 EVP, Innovation, Regulatory + BD, Elanco \u2014 Well-Being Of Animals, People And Planet"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/sUYnXTLIh9c?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>Advancing the well-being of animals, people and the planet \u2014 aaron schacht \u2014 executive vice president, innovation, regulatory &amp; business development, elanco.<\/p>\n<hr>\n<p>Aaron Schacht is Executive Vice President: Innovation, Regulatory + Business Development at Elanco (<a href=\"https:\/\/www.elanco.com\/),\">https:\/\/www.elanco.com\/),<\/a> an American pharmaceutical company which produces medicines and vaccinations for pets and livestock, and which until 2,019 was a subsidiary of Eli Lilly and Company.<\/p>\n<p>Prior to this, Mr. Schacht held a role of Global Brand Development Leader \u2013 Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for Lilly\u2019s novel CGRP neutralizing antibody \u2013 a new potential treatment for prevention of Migraine and Cluster Headache.<\/p>\n<p>In 2,012 Mr. Schacht joined Lilly Biomedicines as Senior Advisor \u2013 Strategy &amp; Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&amp;D Portfolio Management, and Business Development for Lilly BioMedicines \u2013 Lilly\u2019s largest business unit. Past roles included serving as Executive Director, Global External R&amp;D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly\u2019s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&amp;D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry.<\/p>\n<p>In 2,002 during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up.<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2021\/08\/aaron-schacht-evp-innovation-regulatory-bd-elanco-well-being-of-animals-people-and-planet\">Continue reading \u201cAaron Schacht \u2014 EVP, Innovation, Regulatory + BD, Elanco \u2014 Well-Being Of Animals, People And Planet\u201d | &gt;<\/a><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advancing the well-being of animals, people and the planet \u2014 aaron schacht \u2014 executive vice president, innovation, regulatory &amp; business development, elanco. Aaron Schacht is Executive Vice President: Innovation, Regulatory + Business Development at Elanco (https:\/\/www.elanco.com\/), an American pharmaceutical company which produces medicines and vaccinations for pets and livestock, and which until 2,019 was a [\u2026]<\/p>\n","protected":false},"author":400,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,43,19,385],"tags":[],"class_list":["post-126599","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-business","category-chemistry","category-evolution"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/126599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/400"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=126599"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/126599\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=126599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=126599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=126599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}